255 related articles for article (PubMed ID: 17367910)
21. The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity.
Mendoza JL; Schneider WM; Hoffmann HH; Vercauteren K; Jude KM; Xiong A; Moraga I; Horton TM; Glenn JS; de Jong YP; Rice CM; Garcia KC
Immunity; 2017 Mar; 46(3):379-392. PubMed ID: 28329704
[TBL] [Abstract][Full Text] [Related]
22. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response.
François-Newton V; Magno de Freitas Almeida G; Payelle-Brogard B; Monneron D; Pichard-Garcia L; Piehler J; Pellegrini S; Uzé G
PLoS One; 2011; 6(7):e22200. PubMed ID: 21779393
[TBL] [Abstract][Full Text] [Related]
23. Antiviral activity of type I interferons and interleukins 29 and 28a (type III interferons) against Apeu virus.
Almeida GM; de Oliveira DB; Magalhães CL; Bonjardim CA; Ferreira PC; Kroon EG
Antiviral Res; 2008 Dec; 80(3):302-8. PubMed ID: 18657576
[TBL] [Abstract][Full Text] [Related]
24. Targeting IFN-λ: therapeutic implications.
Eslam M; George J
Expert Opin Ther Targets; 2016 Dec; 20(12):1425-1432. PubMed ID: 27681264
[TBL] [Abstract][Full Text] [Related]
25. Balance between IL-3 and type Iinterferons and their interrelationship with FasL dictates lifespan and effector functions of human basophils.
Hagmann BR; Odermatt A; Kaufmann T; Dahinden CA; Fux M
Clin Exp Allergy; 2017 Jan; 47(1):71-84. PubMed ID: 27910206
[TBL] [Abstract][Full Text] [Related]
26. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.
Kotenko SV; Gallagher G; Baurin VV; Lewis-Antes A; Shen M; Shah NK; Langer JA; Sheikh F; Dickensheets H; Donnelly RP
Nat Immunol; 2003 Jan; 4(1):69-77. PubMed ID: 12483210
[TBL] [Abstract][Full Text] [Related]
27. The interferon system of teleost fish.
Robertsen B
Fish Shellfish Immunol; 2006 Feb; 20(2):172-91. PubMed ID: 15939626
[TBL] [Abstract][Full Text] [Related]
28. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.
Marcello T; Grakoui A; Barba-Spaeth G; Machlin ES; Kotenko SV; MacDonald MR; Rice CM
Gastroenterology; 2006 Dec; 131(6):1887-98. PubMed ID: 17087946
[TBL] [Abstract][Full Text] [Related]
29. Interferon (IFN)-λ Takes the Helm: Immunomodulatory Roles of Type III IFNs.
Zanoni I; Granucci F; Broggi A
Front Immunol; 2017; 8():1661. PubMed ID: 29234323
[TBL] [Abstract][Full Text] [Related]
30. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
Zhu H; Butera M; Nelson DR; Liu C
Virol J; 2005 Sep; 2():80. PubMed ID: 16146571
[TBL] [Abstract][Full Text] [Related]
31. Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes.
Yu D; Zhao M; Dong L; Zhao L; Zou M; Sun H; Zhang M; Liu H; Zou Z
Drug Des Devel Ther; 2016; 10():163-82. PubMed ID: 26792983
[TBL] [Abstract][Full Text] [Related]
32. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus.
Chi B; Dickensheets HL; Spann KM; Alston MA; Luongo C; Dumoutier L; Huang J; Renauld JC; Kotenko SV; Roederer M; Beeler JA; Donnelly RP; Collins PL; Rabin RL
J Virol; 2006 May; 80(10):5032-40. PubMed ID: 16641294
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons.
Dickensheets HL; Donnelly RP
J Leukoc Biol; 1999 Mar; 65(3):307-12. PubMed ID: 10080532
[TBL] [Abstract][Full Text] [Related]
34. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity.
Ank N; Iversen MB; Bartholdy C; Staeheli P; Hartmann R; Jensen UB; Dagnaes-Hansen F; Thomsen AR; Chen Z; Haugen H; Klucher K; Paludan SR
J Immunol; 2008 Feb; 180(4):2474-85. PubMed ID: 18250457
[TBL] [Abstract][Full Text] [Related]
35. Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection.
Stoltz M; Klingström J
J Virol; 2010 Sep; 84(18):9140-8. PubMed ID: 20592090
[TBL] [Abstract][Full Text] [Related]
36. Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells.
Tezuka Y; Endo S; Matsui A; Sato A; Saito K; Semba K; Takahashi M; Murakami T
Lung Cancer; 2012 Dec; 78(3):185-92. PubMed ID: 23021208
[TBL] [Abstract][Full Text] [Related]
37. Immune Cell Profiling of IFN-λ Response Shows pDCs Express Highest Level of IFN-λR1 and Are Directly Responsive via the JAK-STAT Pathway.
Kelly A; Robinson MW; Roche G; Biron CA; O'Farrelly C; Ryan EJ
J Interferon Cytokine Res; 2016 Dec; 36(12):671-680. PubMed ID: 27617757
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of type III interferon expression.
Iversen MB; Paludan SR
J Interferon Cytokine Res; 2010 Aug; 30(8):573-8. PubMed ID: 20645874
[TBL] [Abstract][Full Text] [Related]
39. Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity.
Heim A; Weiss S
Med Microbiol Immunol; 2004 May; 193(2-3):149-54. PubMed ID: 13680216
[TBL] [Abstract][Full Text] [Related]
40. The Role of Type III Interferons in Human Disease.
Malik AE; Issekutz TB; Derfalvi B
Clin Invest Med; 2021 Jun; 44(2):E5-18. PubMed ID: 34152702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
